Trehalose-driven TFEB Activation Reprograms Immunosuppressive Macrophages in Glioblastoma
Translational Research · 2026
DOI: 10.1016/j.trsl.2026.05.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2026. Verfasst von Jinlin Pan und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering (Suzhou), Division of Life Science and Medicine, University of Science and Technology of China, China; Suzhou Instit…. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Glioblastoma, Macrophages, Trehalose. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Science and Technology Program of Suzhou, Suzhou City Science and Technology Bureau, National Natural Science Foundation of China.
Abstract (Originalsprache)
Glioblastoma is the most aggressive primary intracranial tumor in adults. It is characterized by a profoundly immunosuppressive tumor microenvironment orchestrated by glioblastoma-associated macrophages. Yet, the molecular signal pathway programming glioblastoma-associated macrophages toward immunosuppressive phenotype remains elusive. Here, we identify transcription factor EB (TFEB) as a critical regulator of macrophage-driven immune suppression in glioblastoma. In human glioblastoma samples, TFEB is upregulated and correlates with macrophage and CD4⁺ T-cell infiltration. However, higher TFEB levels unexpectedly are associated with improved patient survival, while myeloid-specific TFEB ablation accelerates tumor progression with high glioblastoma-associated macrophage infiltration and impairs T-cell priming. Mechanistically, TFEB loss engages p38 MAPK/ERK axis, enhancing autophagic flux and reinforcing immunosuppressive polarization. In contrast, pharmacologic activation of TFEB with trehalose remodels the TME toward an immuno-stimulatory state and markedly suppresses tumor growth. Collectively, our findings position TFEB as a critical regulator of glioblastoma-associated macrophage polarization and provide a deep insight into TFEB-independent modulation as a promising strategy to overcome immunosuppression in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Engineering (Suzhou), Division of Life Science and Medicine, University of Science and Technology of China, China; Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Scien…
- School of Veterinary Medicine and Biosafety, Lanzhou University, Lanzhou, China.
- Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China.
- XJTLU Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, China.
- Institute of Biomedical and Genetic Engineering, Islamabad, Pakistan.
- Institute of Pharmaceutical Sciences (KMU-IPS), Khyber Medical University (KMU), Peshawar.
Förderung
- Science and Technology Program of Suzhou
- Suzhou City Science and Technology Bureau
- National Natural Science Foundation of China
- Chinese Academy of Sciences
Zitieren
APA
Pan, J., Zhao, Y., Han, Y., Zhang, J., Zhao, R., Hong, L., Qu, S., Ahmad, N., Siraj, S., Huang, X., Fu, P., Yang, J., Zhou, Y., & Sun, M. (2026). Trehalose-driven TFEB Activation Reprograms Immunosuppressive Macrophages in Glioblastoma. Translational Research. https://doi.org/10.1016/j.trsl.2026.05.005
Vancouver
Pan J, Zhao Y, Han Y, Zhang J, Zhao R, Hong L, et al. Trehalose-driven TFEB Activation Reprograms Immunosuppressive Macrophages in Glioblastoma. Translational Research. 2026. doi:10.1016/j.trsl.2026.05.005
BibTeX
@article{Pan2026,
author = {Pan, Jinlin and Zhao, Yu and Han, Yuwen and Zhang, Jun and Zhao, Rongchuan and Hong, Lei and Qu, Siying and Ahmad, Nafees and Siraj, Sami and Huang, Xia and Fu, Peng and Yang, Jiao and Zhou, Yuanshuai and Sun, Minxuan},
title = {Trehalose-driven TFEB Activation Reprograms Immunosuppressive Macrophages in Glioblastoma},
journal = {Translational Research},
year = {2026},
doi = {10.1016/j.trsl.2026.05.005}
}
EUVIMED